HIND Form 4: Mohanjit Jolly reports 454k Vyome shares post-merger

Rhea-AI Filing Summary

Vyome Holdings, Inc. director reports new share ownership following merger. A Form 4 discloses that Mohanjit Jolly, a director of Vyome Holdings (ticker HIND), acquired 454,456 shares of the company’s common stock on 08/15/2025. The shares were received in connection with a merger in which Raider Lifesciences Inc., a wholly owned subsidiary of Vyome Holdings, merged with Vyome Therapeutics, Inc., which became a subsidiary of Vyome Holdings.

Under the merger terms, each 5,000 shares of Vyome Therapeutics common or preferred stock were converted into 1 share of Vyome Holdings common stock. Jolly received the 454,456 Vyome Holdings shares in exchange for 2,272,280,000 shares of Vyome Therapeutics stock. The filing states these shares are held indirectly through Iron Pillar Fund I Ltd., where Jolly is a general partner and an advisor/representative for related investments.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Jolly Mohanjit

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	454,456	$0.00	--

Holdings After Transaction: Common Stock — 454,456 shares (Indirect, See footnote)

Footnotes (1)

1. Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 454,456 shares of the Issuer's common stock in exchange for 2,272,280,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement. Includes indirect beneficial ownership of 454,456 shares of common stock held by Iron Pillar Fund I Ltd. Mohanjit Jolly is a general partner of Iron Pillar Fund I Ltd. and an advisor to and representative of Iron Pillar India Fund I for investments in the Issuer.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jolly Mohanjit

(Last) (First) (Middle)

HARVARD SQUARE,

ONE MIFFLIN PLACE, SUITE 400

(Street)

CAMBRIDGE MA 02138

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vyome Holdings, Inc [ HIND ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2025		A(1)		454,456	A	(1)	454,456	I	See footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 454,456 shares of the Issuer's common stock in exchange for 2,272,280,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement.

2. Includes indirect beneficial ownership of 454,456 shares of common stock held by Iron Pillar Fund I Ltd. Mohanjit Jolly is a general partner of Iron Pillar Fund I Ltd. and an advisor to and representative of Iron Pillar India Fund I for investments in the Issuer.

	/s/ Mohanjit Jolly	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Vyome Holdings (HIND) report in this Form 4?

The Form 4 reports that director Mohanjit Jolly acquired 454,456 shares of Vyome Holdings common stock on 08/15/2025 as part of a merger involving Vyome Therapeutics, Inc.

How did Mohanjit Jolly receive 454,456 Vyome Holdings (HIND) shares?

Jolly received 454,456 Vyome Holdings shares when Raider Lifesciences Inc., a wholly owned subsidiary of Vyome Holdings, merged with Vyome Therapeutics, Inc.. His Vyome Therapeutics shares were converted into Vyome Holdings shares under the merger agreement.

What were the share exchange terms in the Vyome Holdings and Vyome Therapeutics merger?

Under the merger terms, each share of common or preferred stock of Vyome Therapeutics was converted into the right to receive 1 Vyome Holdings common share for every 5,000 Vyome Therapeutics shares.

How many Vyome Therapeutics shares did Mohanjit Jolly exchange in the merger?

The filing states that Mohanjit Jolly received 454,456 Vyome Holdings shares in exchange for 2,272,280,000 shares of Vyome Therapeutics common stock under the merger agreement.

Is Mohanjit Jolly’s ownership in Vyome Holdings (HIND) direct or indirect?

The Form 4 reports indirect beneficial ownership of 454,456 shares of Vyome Holdings common stock held by Iron Pillar Fund I Ltd., where Jolly is a general partner and an advisor/representative for investments in Vyome Holdings.

How did Vyome Holdings, Inc. get its current name?

Following the merger in which Raider Lifesciences Inc. merged with Vyome Therapeutics, the issuer was renamed "Vyome Holdings, Inc.", while Vyome Therapeutics continued as Vyome Therapeutics, Inc. as a subsidiary.